Chronic Granulomatous Disease or CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. In 1990, Actimmune® (interferon gamma-1b) was approved by the FDA for reducing the frequency and the severity of serious infections associated with CGD, and is the only FDA approved drug for this rare disease.

Actimmune is the only FDA approved drug for this disease.

The most commons side effects are flu-like symptoms, including fever, headache and chills.